Laboratory Cost and Quality Review service
AssayIQ connects reimbursement scenarios with the laboratory's actual test mix, costs, rework, and workflow. Directors receive an operational plan; corporate and finance teams receive a transparent model with assumptions, limitations, and approval points.
When to call
What you receive
Approach
CMS released preliminary CY 2027 CLFS information on September 21, 2026 and states that final rates will be published in November 2026. As of October 5, this service uses preliminary figures only as scenarios. A national weighted-median change is not a forecast of the client's total revenue loss.
Use aggregate test volumes, payer mix, actual reimbursement, reagent and consumable costs, referral fees, repeats, and agreed staff-cost assumptions. No patient identifiers belong in the public intake. A proposal specifies the data period, coding reviewer, review date, turnaround, and whether a final-rate refresh is included.
From $5,000 within the Laboratory Cost and Quality Review for one defined laboratory or process. Additional sites, broader test menus, data reconstruction, implementation, and recurring monitoring are quoted separately. A defined multi-site pilot starts at $25,000 under the corporate program.
Separate reduced expenditure from returned staff capacity, revenue changes, and modeled cost avoidance. Client finance validates the baseline and any realized result. Review corrected reports, QC exceptions, turnaround, and service availability before expanding a cost change.
Financial scenarios are estimates, not guaranteed reimbursement or savings. AssayIQ does not submit payer claims or determine clinical necessity. Qualified client billing, finance, clinical, procurement, and laboratory leaders validate assumptions and authorize changes.
Discuss the priority
We will determine whether a focused AssayIQ scope is a practical fit. Do not send protected health information through the public form or ordinary email.